Stay updated on Lebrikizumab Impact on Vaccine Response in Atopic Dermatitis Clinical Trial
Sign up to get notified when there's something new on the Lebrikizumab Impact on Vaccine Response in Atopic Dermatitis Clinical Trial page.

Latest updates to the Lebrikizumab Impact on Vaccine Response in Atopic Dermatitis Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe site revision tag was updated from v3.4.1 to v3.4.2; there are no changes to study details, eligibility criteria, or results presented on the page.SummaryDifference0.0%

- Check18 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1 on the page. This appears to be a maintenance/version update without changes to core study content or user-facing features.SummaryDifference0.0%

- Check33 days agoChange DetectedIntroduces Show glossary and Hide glossary options and adds labels such as 'Last Update Submitted that Met QC Criteria' with revision text. These changes are mainly UI and metadata tweaks and do not alter core study content.SummaryDifference0.2%

- Check40 days agoChange DetectedRevision label updated to v3.3.4, replacing the previous v3.3.3.SummaryDifference0.0%

- Check62 days agoChange DetectedAdded a consolidated Locations section listing participating sites by state (Alabama, Arkansas, California, Colorado, etc.) and updated the revision to v3.3.3. The previous standalone location blocks and the HHS Vulnerability Disclosure text were replaced.SummaryDifference2%

- Check92 days agoChange DetectedThe Publications section text now states that publications are automatically filled from PubMed, replacing the prior wording. The page revision has been updated to v3.3.2 (from v3.2.0).SummaryDifference0.1%

Stay in the know with updates to Lebrikizumab Impact on Vaccine Response in Atopic Dermatitis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lebrikizumab Impact on Vaccine Response in Atopic Dermatitis Clinical Trial page.